New bacteria slurry takes on poop transplants for stubborn gut infection
NCT ID NCT05911997
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two treatments for people with repeat C. diff infections: a lab-made bacteria mix called MTC01 and a fecal transplant (FMT) from a healthy donor. Both are given during a colonoscopy. The goal is to see which is safer and better at stopping the infection from coming back. About 60 adults with at least two recent C. diff episodes will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MTC01 (a slurry of bacteria) and fecal microbiota transplantation (FMT) from a healthy donor
- What this could lead to
- If successful, this could point toward a safer, more effective treatment for recurrent C. difficile infections, reducing the need for repeated antibiotics.
- What could go wrong
- This is an early Phase 1 trial with only 60 participants, so results may not apply broadly. There are risks of serious side effects, including infection or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIODIES DIFFICILE INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States